BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$82.08B, compared with -$46.69M a year earlier. Trailing-twelve-month operating income was -$81.76B. Over 3 fiscal years it compounded at +49.1% a year.
Context
- Operating income amounted to 16.6% of revenue in FY2025, down 0.4 pp from a year earlier.
- Operating income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 20 analysts of $719.22M (+34.8%) for the fiscal year ending Dec 2026, a step up from the +10.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$82.08B-74093.5% QoQ
- Last fiscal yearDec 2025
- $533.48M+10.2% YoY
- LTMSep 2026
- -$81.76B-13383.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 533.48M USD
- Year-over-year change
- +10.2%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 533.48M | +10.2% |
| FY2024 | 2024-12-31 | 484.21M | +160.6% |
| FY2023 | 2023-12-31 | 185.77M | +15.4% |
| FY2022 | 2022-12-31 | 160.97M | +295.5% |
| FY2021 | 2021-12-31 | (82.34M) | — |
Operating Income vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13383.8% is the lowest of 11, against a peer median of +13.7%.
- Operating income amounts to 8.0% of revenue for BMRN, versus a peer median of 27.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.4B USD | +10.1% | +3.4% | 33.9% | |
| LTM Jun 2026 | $999.78M USD | +654.9% | — | 20.8% | |
| LTM Sep 2026 | €222.29M EUR | +252.5% | — | 18.4% | |
| LTM Jun 2026 | $116.26M USD | -83.8% | — | 11.5% | |
| LTM Mar 2026 | $23.38M USD | +3514.0% | +4.6% | 6.3% | |
| LTM Sep 2026 | -$133.49M USD | -46.5% | — | 20.5% | |
| LTM Jun 2026 | -$543.47M USD | +17.2% | — | 76.2% | |
| LTM Mar 2026 | -$561.78M USD | -9.4% | — | 83.9% | |
| LTM Sep 2026 | -$565.42M USD | -103.4% | — | 58.9% | |
| LTM Jun 2026 | -$817.54M USD | +18.6% | — | 71.9% | |
| LTM Sep 2026 | -$81.76B USD | -13383.8% | +49.1% | 8.0% | |
| Peer median (excluding BMRN) | — | +13.7% | +4.0% | 27.3% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.